(ELAN) Elanco Animal Health - Ratings and Ratios
Parasiticides, Vaccines, Therapeutics, Antibiotics, Insecticides
ELAN EPS (Earnings per Share)
ELAN Revenue
Description: ELAN Elanco Animal Health
Elanco Animal Health (NYSE:ELAN) is a global animal health company that develops, manufactures, and markets a diverse portfolio of products for pets and farm animals, driving innovation in the industry. The company offers a broad range of pet health products, including parasiticides, vaccines, and therapeutics, under various trademarks, catering to the needs of pet owners and veterinarians.
The companys product portfolio for pets includes well-known brands such as Seresto, Credelio, and Trifexis, which provide protection against fleas, ticks, and internal parasites, as well as treatments for pain, otitis, and dermatology indications. In the farm animal segment, Elanco offers medicated feed additives, injectable antibiotics, and vaccines under trademarks like Rumensin and Baytril, helping farmers improve animal health and wellbeing.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenses as a percentage of sales can be considered. For instance, a rising gross margin could indicate improving operational efficiency, while a significant investment in R&D (around 10-15% of sales) could be a positive sign for future innovation and growth. Additionally, metrics like return on equity (RoE) and return on assets (RoA) can provide insights into the companys profitability and asset utilization.
From a financial perspective, Elancos market capitalization stands at approximately $7.4 billion, with a forward price-to-earnings (P/E) ratio of 17.18, indicating the markets expectations for the companys future earnings growth. The companys ability to generate cash from operations and its debt-to-equity ratio are also important metrics to assess its financial health and leverage.
ELAN Stock Overview
| Market Cap in USD | 10,642m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2018-09-20 |
ELAN Stock Ratings
| Growth Rating | 41.1% |
| Fundamental | 49.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 47.2% |
| Analyst Rating | 3.87 of 5 |
ELAN Dividends
Currently no dividends paidELAN Growth Ratios
| Growth Correlation 3m | 95.2% |
| Growth Correlation 12m | 63.8% |
| Growth Correlation 5y | -64.2% |
| CAGR 5y | 17.73% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.32 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.85 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | 43.74 |
| Beta | 1.649 |
| Volatility | 36.62% |
| Current Volume | 3458.7k |
| Average Volume 20d | 4922.3k |
| Stop Loss | 20.9 (-3.3%) |
| Signal | 1.06 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (434.0m TTM) > 0 and > 6% of Revenue (6% = 269.0m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -0.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 49.55% (prev 58.79%; Δ -9.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 572.0m > Net Income 434.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.67b) to EBITDA (1.53b) ratio: 2.40 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (500.1m) change vs 12m ago 1.19% (target <= -2.0% for YES) |
| Gross Margin 42.98% (prev 43.12%; Δ -0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.60% (prev 32.64%; Δ -0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.20 (EBITDA TTM 1.53b / Interest Expense TTM 270.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.73
| (A) 0.16 = (Total Current Assets 3.61b - Total Current Liabilities 1.39b) / Total Assets 13.74b |
| (B) -0.14 = Retained Earnings (Balance) -1.87b / Total Assets 13.74b |
| (C) 0.06 = EBIT TTM 863.0m / Avg Total Assets 13.75b |
| (D) -0.30 = Book Value of Equity -2.06b / Total Liabilities 6.97b |
| Total Rating: 0.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.75
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 2.48% = 1.24 |
| 3. FCF Margin 7.92% = 1.98 |
| 4. Debt/Equity 0.62 = 2.31 |
| 5. Debt/Ebitda 2.40 = -0.78 |
| 6. ROIC - WACC (= -5.34)% = -6.68 |
| 7. RoE 6.74% = 0.56 |
| 8. Rev. Trend 38.13% = 2.86 |
| 9. EPS Trend -25.02% = -1.25 |
What is the price of ELAN shares?
Over the past week, the price has changed by +6.92%, over one month by +13.61%, over three months by +47.28% and over the past year by +71.32%.
Is Elanco Animal Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELAN is around 21.48 USD . This means that ELAN is currently overvalued and has a potential downside of -0.65%.
Is ELAN a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.6 | -4.9% |
| Analysts Target Price | 20.6 | -4.9% |
| ValueRay Target Price | 24 | 11.1% |
Last update: 2025-10-20 03:50
ELAN Fundamental Data Overview
P/E Trailing = 24.3409
P/E Forward = 20.5339
P/S = 2.3733
P/B = 1.5011
P/EG = 8.9357
Beta = 1.649
Revenue TTM = 4.48b USD
EBIT TTM = 863.0m USD
EBITDA TTM = 1.53b USD
Long Term Debt = 4.15b USD (from longTermDebt, last quarter)
Short Term Debt = 61.0m USD (from shortTermDebt, last quarter)
Debt = 4.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.67b USD (from netDebt column, last quarter)
Enterprise Value = 14.31b USD (10.64b + Debt 4.21b - CCE 539.0m)
Interest Coverage Ratio = 3.20 (Ebit TTM 863.0m / Interest Expense TTM 270.0m)
FCF Yield = 2.48% (FCF TTM 355.0m / Enterprise Value 14.31b)
FCF Margin = 7.92% (FCF TTM 355.0m / Revenue TTM 4.48b)
Net Margin = 9.68% (Net Income TTM 434.0m / Revenue TTM 4.48b)
Gross Margin = 42.98% ((Revenue TTM 4.48b - Cost of Revenue TTM 2.56b) / Revenue TTM)
Gross Margin QoQ = 46.49% (prev 46.61%)
Tobins Q-Ratio = 1.04 (Enterprise Value 14.31b / Total Assets 13.74b)
Interest Expense / Debt = 1.66% (Interest Expense 70.0m / Debt 4.21b)
Taxrate = 56.00% (14.0m / 25.0m)
NOPAT = 379.7m (EBIT 863.0m * (1 - 56.00%))
Current Ratio = 2.60 (Total Current Assets 3.61b / Total Current Liabilities 1.39b)
Debt / Equity = 0.62 (Debt 4.21b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 2.40 (Net Debt 3.67b / EBITDA 1.53b)
Debt / FCF = 10.34 (Net Debt 3.67b / FCF TTM 355.0m)
Total Stockholder Equity = 6.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.16% (Net Income 434.0m / Total Assets 13.74b)
RoE = 6.74% (Net Income TTM 434.0m / Total Stockholder Equity 6.44b)
RoCE = 8.15% (EBIT 863.0m / Capital Employed (Equity 6.44b + L.T.Debt 4.15b))
RoIC = 3.53% (NOPAT 379.7m / Invested Capital 10.76b)
WACC = 8.87% (E(10.64b)/V(14.85b) * Re(12.09%) + D(4.21b)/V(14.85b) * Rd(1.66%) * (1-Tc(0.56)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.74%
[DCF Debug] Terminal Value 54.64% ; FCFE base≈383.0m ; Y1≈251.5m ; Y5≈115.0m
Fair Price DCF = 2.71 (DCF Value 1.35b / Shares Outstanding 496.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -25.02 | EPS CAGR: -58.55% | SUE: -3.21 | # QB: 0
Revenue Correlation: 38.13 | Revenue CAGR: 7.16% | SUE: 4.0 | # QB: 2
Additional Sources for ELAN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle